Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenues:
Clinical treatment programs	$ 45	$ 35	$ 123	$ 108
Total revenues	45	35	123	108
Costs and expenses:
Production/cost of goods sold	217	181	614	649
Research and development	1,750	1,808	5,014	5,498
General and administrative	1,635	1,738	4,890	5,495
Total costs and expenses	3,602	3,727	10,518	11,642
Operating loss	(3,557)	(3,692)	(10,395)	(11,534)
Interest expense from capital leases	(9)	(5)	(21)	(5)
Interest and other income	212	443	686	565
Funds received from sale of income tax net operating losses (Note 15)	0	0	2,272	0
Redeemable warrants valuation adjustment (Note 12)	614	(584)	1,558	341
Net loss	(2,740)	(3,838)	(5,900)	(10,633)
Unrealized gain (loss) on investments (Notes 5, 6, and 14)	(529)	719	107	717
Net comprehensive loss (Note 14)	$ (3,269)	$ (3,119)	$ (5,793)	$ (9,916)
Basic and diluted loss per share (Note 2)	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.08)
Weighted average shares outstanding, basic and diluted	135,496,311	134,869,730	135,379,622	133,605,973